NEWS & EVENTS

Catalent today announced that it has completed a $10 million expansion at its Malvern, Pennsylvania, and Dartford, U.K., facilities, to provide advanced containment capabilities for the micronization of highly potent drug compounds.

Catalent today announced the launch of its new Xpress Pharmaceutics® service, designed to accelerate the development of oral drugs through Phase 1 clinical studies.

Catalent today announced that it has increased cold chain packaging capabilities at its Philadelphia facility to support increased demand for the distribution of biologic drugs, and advanced cell and gene therapies.

Catalent today announced that its Board of Directors has appointed Alessandro Maselli, currently President and Chief Operating Officer, as the company’s next President and Chief Executive Officer, effective July 1, 2022.

NurOwn is BrainStorm’s autologous cellular therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (PMS) and other neurodegenerative diseases.

The selection follows a seven-month formulation development program conducted by Catalent, in which the API was screened for ideal formulation conditions, with a number of potential excipients, to come up with a drug product that suits ProtoKinetix’s needs.

Catalent today announced that three of its experts will be speaking on current market trends and strategies within the industry at two upcoming conferences, Outsourcing in Clinical Trials East Asia, and Outsourcing in Clinical Trials Southern California 2021.

Catalent today announced the opening a new facility in San Diego, in response to increased demand from pharmaceutical and biopharmaceutical customers for integrated development, clinical packaging, and distribution solutions on the U.S. West Coast.

Catalent today announced a $230 million expansion project to add three further commercial-scale viral vector manufacturing suites and associated support facilities and services at its gene therapy campus in Harmans, Maryland, to meet growing customer demand.